ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO

3

Sept 21 (Reuters) – ADARx Pharmaceuticals is seeking a valuation of up to $1.74 billion in its U.S. initial public offering, the company said on Monday, as investor appetite for biotech listings

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)